This clinical trial is focused on studying the effects of a medication called letrozole in patients with epithelial ovarian cancer. Epithelial ovarian cancer is a type of cancer that begins in the layer of cells covering the ovaries. The study aims to evaluate how effective letrozole is as a maintenance therapy after patients have undergone standard treatments, which typically include surgery and chemotherapy. Maintenance therapy is a treatment given to help keep cancer from coming back after it has responded to initial treatment.

Participants in the study will be randomly assigned to receive either letrozole or a placebo, which is a tablet that looks like the medication but does not contain any active ingredients. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving letrozole and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The main goal is to see if letrozole can help extend the time patients live without their cancer getting worse, known as progression-free survival.

The study will take place over a period of time, with participants taking the medication or placebo orally for up to 60 months. Throughout the study, participants will have regular check-ups to monitor their health and the status of their cancer. The researchers will also look at other outcomes, such as overall survival and quality of life, to understand the full impact of letrozole as a maintenance therapy for epithelial ovarian cancer.